Methyl-aminolevulinate photodynamic therapy for the treatment of erythroplasia of Queyrat in 23 patients.

Abstract

Erythroplasia of Queyrat (EQ) is an intraepithelial squamous cell carcinoma localized on the mucosal or transitional surfaces. Standard therapy usually consists of the surgical removal of the cancer. The use of non-invasive alternative procedures, such as photodynamic therapy (PDT), has been considered for the treatment of EQ, although only a few reports regarding isolated cases or small series exist. We describe our cumulative experience with PDT, using topical methyl-aminolevulinate (MAL), for the management of 23 male patients with EQ of the glans penis and/or prepuce. Patients underwent two consecutive weekly MAL-PDT sessions, with the second session postponed in seven patients because of an excessive local reaction. Nineteen patients obtained a complete clinical remission without any sign of recurrence over an average post-treatment period of 18 months (range, 8-30 months). Cosmetic outcome was excellent in most patients, while dyschromic changes occurred in four cases. All patients experienced transient local adverse reactions and 22 of them reported severe or very severe symptoms during the session.

• Authors: Dario Fai, Ivana Romano, Nicoletta Cassano, Gino A Vena
• Journal: The Journal of dermatological treatment (J Dermatolog Treat) Vol. 23 Issue 5 Pg. 330-2 (Oct 2012) ISSN: 1471-1753 [Electronic] England
• PMID: 21888568 (Publication Type: Journal Article)

Chemical References

• Photosensitizing Agents
• methyl 5-aminolevulinate
• Aminolevulinic Acid

Topics

• Adult
• Aged
• Aged, 80 and over
• Aminolevulinic Acid (adverse effects, analogs & derivatives, therapeutic use)
• Carcinoma, Squamous Cell (drug therapy)
• Erythroplasia (drug therapy)
• Humans
• Male
• Middle Aged
• Penile Neoplasms (drug therapy)
• Photochemotherapy (adverse effects)
• Photosensitizing Agents (adverse effects, therapeutic use)